Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Proof of concept study of RECCE 327 topical anti-infective therapy for mild skin and soft tissue diabetes foot infections

Next Previous
Trial Profile

Proof of concept study of RECCE 327 topical anti-infective therapy for mild skin and soft tissue diabetes foot infections

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RECCE 327 (Primary)
  • Indications Diabetic foot ulcer; Skin and soft tissue infections
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Recce Pharmaceuticals

Most Recent Events

  • 27 Feb 2024 According to a Recce Pharmaceuticals media release, based on the interim data analysis and the study achieving its primary endpoints. The company announced the expansion of this trial, in the coming months, additional study sites both Australia and overseas will become active and include the broader patient population in the study.
  • 23 Jan 2024 Results were presented in a Recce Pharmaceuticals Media Release.
  • 23 Jan 2024 Primary endpoint (Number of participants demonstrating DFI resolution as assessed by a change in score of the Diabetic Foot Infection Wound Scoring Scale and the Wound, Ischaemia and foot Infection (WIfI) classification 2)Number of participants demonstrating healing as assessed by a change in score of the Diabetic Foot Infection Wound Scoring Scale and the Wound, Ischaemia and foot Infection (WIfI) classification) has been met, according to a Recce Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top